Stacey Martinez — VP Go-to-Market Revision · 2026-06-02

Launch Line Advisory · In response to your 6/2 reply · Non-binding · Definitive Advisor Agreement + Equity Grant to follow from counsel
Revised compensation structure (forward cash, no pre-revenue debt accrual), 3-stage cap table, and a scenario framework for thinking about valuation.

1 · Terms — proposed structure

Your reply asked for a cash component. This structure preserves the 6% equity and addresses the cash question through forward cash, not back cash — meaning cash kicks in when Launch Line can actually pay it from operations or fresh capital, rather than accruing as a balance-sheet liability during the runway period. Hard principle: no debt on Launch Line's books pre-revenue.

Lever Term
Engagement term12 months
Commitment~25% time, ~10 hr/wk
Cash during engagement (pre-revenue)$0/month, no accrual, no contingent liability
Equity grant (day 1)6.00% fully-diluted common
VestingMonthly, 1/12 each over 12 months, no cliff, no performance gate
Forward cash — Path A (operating profitability)Upon Launch Line achieving trailing-3-month operating profit ≥ $50K/mo, you convert to $4,000/month forward salary, paid from operations. Continues for remainder of engagement or as renewed.
Forward cash — Path B (Series A signing bonus)If a priced Series A (≥$5M) closes before operating profitability, a one-time founding-team bonus is paid to you from round proceeds (sized at $4K × months of active engagement through close; carved out at term sheet stage from fresh investor capital — not back-pay on operations).
Pro-rata distribution rightsParticipates in any operating distributions to common holders
Secondary participation rightPro-rata if founder secondary or unsolicited M&A
Effective dateSigning of definitive Advisor Agreement
Launch Line pre-revenue cash burn$0 — no accrual, no balance-sheet liability
Why forward cash (not deferred / notional accrual): a notional accrual creates a contingent liability that sits on the balance sheet, shows up in due diligence, and undercuts the "bootstrapped + clean books" story Launch Line is committed to. The forward structure is cleaner: cash flows only when there's actually cash to pay it — either from operations you helped build, or from Series A proceeds. Aligns your incentives with the same outcomes Launch Line is optimizing for, no debt accrues, story stays honest.

2 · Cap table — bootstrap-to-A, three stages

No seed round modeled. Launch Line bootstraps on revenue through Series A.

Holder Founding Yr-1 grants Post-Series A
Jeff Giuzio — Founder100.00%90.25%63.18%
Stacey Martinez — VP GTM6.00%4.20%
Kara Witalis — Advisor (healthcare governance)3.00%2.10%
Joey — Summer intern (Owl) *up to 0.25%up to 0.18%
Dominic — Summer intern (Falcon) *up to 0.25%up to 0.18%
Arthur — Summer intern (Sparrow) *up to 0.25%up to 0.18%
Option pool (unallocated)10.00%
Series A investors20.00%
Total100.00%100.00%100.00%
Assumptions — Series A modeled at $8-10M raised @ ~$40M post-money (revenue-priced, not seed-priced), 20% sold to investors, 10% post-money option pool refresh coming out of pre-money. No seed round between Yr-1 grants and Series A.
* Summer intern grants are conditional on end-of-summer performance review. Each intern's vertical (Joey/Owl, Dominic/Falcon, Arthur/Sparrow) has measurable summer deliverables; grants are made only if those deliverables land. Any unawarded portion remains in the founder pool. Your percentages above are reported on the conservative case (interns fully earn). If no intern earns, your post-A position is 4.25% rather than 4.20% — immaterial to your economics, flagged here for transparency.

Key takeaways on the cap table

3 · Valuation — scenarios, not a current FMV

How to think about value: there isn't a defensible current FMV for Launch Line equity today. No 409A valuation, no priced round, no revenue. Rather than anchoring on a paper number, the framework below outlines the scenarios this engagement is underwriting toward — anchored in comparable healthcare-SaaS exits. Real price discovery comes with Series A or an acquisition offer, 18-30 months out.

Scenario framework

Scenario Path Stacey's % Paper value
No tractionNo A, no acquisition6.00%$0
Modest bootstrap success$1-2M ARR, no A, profitable6.00%$600K – $1.2M (5-10× ARR)
Series A on revenue$3-5M ARR, A at ~$40M post4.20%~$1.7M paper
Strong outcome / M&AAcquired at $100-200M4.20-6.00%$4M – $12M
Multiples anchored in healthcare-SaaS comparables (Sg2, Definitive Healthcare, IntelliMed-class transactions). Not a forecast. Range demonstrates the case Launch Line is underwriting, not a guarantee of any outcome.

Honest framing for the email

"There's no FMV today because there's no revenue. The first real price discovery is Series A or an acquisition offer — both 18-30 months out. Here's the case we're underwriting; tell me where you think it's wrong."

4 · Open items to discuss

  1. Forward-cash trigger threshold. Proposed at trailing-3-month operating profit ≥ $50K/mo. Open to refining the threshold.
  2. Series A bonus sizing. Proposed at $4K × months of active engagement through close (caps naturally at elapsed time). Defaults to flat $48K if simpler is preferred.
  3. Counsel engagement. Definitive Advisor Agreement and Equity Grant docs to be drafted by counsel before signing. Target effective date no later than 7/15.
  4. Cap table. Section 2 reflects current cap table plus all anticipated Year-1 grants. Updated cap table will be re-confirmed at signing.